Sattva S. Neelapu, MD | Authors

Sattva S. Neelapu, MD, Discusses Further ZUMA-5 Follow-up on Axi-Cel for R/R iNHL

December 16, 2021

Sattva S. Neelapu, MD, spoke about continuing to look at results from the ZUMA-5 trial to determine if axicabtagene ciloleucel can cure patients with relapsed or refractory indolent non-Hodgkin lymphoma

Sattva S. Neelapu, MD, Discusses Interesting Abstracts at 2021 ASH

December 14, 2021

Sattva S. Neelapu, MD, spoke about which abstracts he was most excited to see presented at the upcoming American Society of Hematology Annual Meeting.

Sattva S. Neelapu, MD, Discusses the Results of the ZUMA-5 Trial With Axi-Cel in R/R iNHL

December 12, 2021

Sattva S. Neelapu, MD, spoke about the ZUMA-5 trial and the long-term follow-up results seen with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma.